ACCURETIC Drug Patent Profile
✉ Email this page to a colleague
When do Accuretic patents expire, and what generic alternatives are available?
Accuretic is a drug marketed by Pfizer Pharms and is included in one NDA.
The generic ingredient in ACCURETIC is hydrochlorothiazide; quinapril hydrochloride. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; quinapril hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ACCURETIC?
- What are the global sales for ACCURETIC?
- What is Average Wholesale Price for ACCURETIC?
Summary for ACCURETIC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 128 |
| Clinical Trials: | 3 |
| Patent Applications: | 3,430 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ACCURETIC |
| What excipients (inactive ingredients) are in ACCURETIC? | ACCURETIC excipients list |
| DailyMed Link: | ACCURETIC at DailyMed |
Recent Clinical Trials for ACCURETIC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ranbaxy Laboratories Limited | N/A |
| Mylan Pharmaceuticals | Phase 1 |
Pharmacology for ACCURETIC
| Drug Class | Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
| Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for ACCURETIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-001 | Dec 28, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-002 | Dec 28, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-003 | Dec 28, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ACCURETIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-003 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-003 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-001 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-002 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-002 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ACCURETIC
See the table below for patents covering ACCURETIC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 198542 | ACYL DERIVATIVES OF 1,2,3,4-TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES | ⤷ Sign Up |
| Austria | 26120 | ⤷ Sign Up | |
| Hungary | 183602 | PROCESS FOR PRODUCING 1,2,3,4-TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID'S SUBSTITUTED ACYL DERIVATIVES | ⤷ Sign Up |
| Philippines | 26279 | Stabilized compositions | ⤷ Sign Up |
| Hong Kong | 43389 | SUBSTITUTED ACYL DERIVATIVES OF 1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACIDS,SALTS THEREOF,PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR SALTS,AND THE PRODUCTION OF THE SAME | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ACCURETIC
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0096157 | SPC/GB95/011 | United Kingdom | ⤷ Sign Up | SPC/GB95/011:, EXPIRES: 20060930 |
| 0454511 | SPC/GB99/008 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
| 0502314 | C300095 | Netherlands | ⤷ Sign Up | PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419 |
| 0503785 | CA 2011 00026 | Denmark | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216 |
| 0049605 | SPC/GB93/099 | United Kingdom | ⤷ Sign Up | SPC/GB93/099, EXPIRES: 20040413 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
